Drug Trial Radar · NCT06212999
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
617
Actual
Start
Jan 30, 2024
Primary completion
Dec 26, 2026
Study completion Dec 26, 2026
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Jan 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).
Conditions
- Hidradenitis Suppurativa (HS)
Interventions
PovorcitinibDrug
Oral; Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with Treatment-Emergent Adverse Events (TEAEs)Time frame: up to approximately 56 weeks
Locations
165 sites in 17 countries. Site status is shown where the registry gives one.
Investigative Site US303
Phoenix, Arizona
Investigative Site US240
Scottsdale, Arizona
Investigative Site US307
Fort Smith, Arkansas
Investigative Site US214
Rogers, Arkansas
Investigative Site US315
Laguna Niguel, California
Investigative Site US223
Los Angeles, California
Investigative Site US222
Oakland, California
Investigative Site US226
San Diego, California
Investigative Site US309
Clearwater, Florida
Investigative Site US317
Hialeah, Florida
Investigative Site US306
Hollywood, Florida
Investigative Site US320
Hollywood, Florida
Investigative Site US316
Maitland, Florida
Investigative Site US227
Margate, Florida
Investigative Site US204
Miami, Florida
Investigative Site US236
Miami, Florida
Investigative Site US321
North Miami Beach, Florida
Investigative Site US200
Ocala, Florida
Investigative Site US228
Tampa, Florida
Investigative Site US201
Tampa, Florida
Investigative Site US311
Marietta, Georgia
Investigative Site US220
West Dundee, Illinois
Investigative Site US206
Indianapolis, Indiana
Investigative Site US337
Indianapolis, Indiana
Investigative Site US341
Bowling Green, Kentucky
Investigative Site US209
Louisville, Kentucky
Investigative Site US305
Baton Rouge, Louisiana
Investigative Site US207
Metairie, Louisiana
Investigative Site US229
New Orleans, Louisiana
Investigative Site US224
Baltimore, Maryland
Investigative Site US325
Marriottsville, Maryland
Investigative Site US225
Boston, Massachusetts
Investigative Site US304
Boston, Massachusetts
Investigative Site US310
Brighton, Massachusetts
Investigative Site US221
Quincy, Massachusetts
Investigative Site US213
Fort Gratiot, Michigan
Investigative Site US217
Waterford, Michigan
Investigative Site US212
Minneapolis, Minnesota
Investigative Site US302
St Louis, Missouri
Investigative Site US318
Portsmouth, New Hampshire
Showing 40 of 165 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.